Synteract acquires KinderPharm to be ‘one-stop shop’ for pediatric clinical trials

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/KatarzynaBialasiewicz)
(Image: Getty/KatarzynaBialasiewicz)

Related tags Synteract KinderPharm Pediatrics Drug development Clinical trials

Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.

Synteract CEO Steve Powell said the combined contract research organization (CRO) will offer biopharma a “one-stop shop solution for bringing their pediatric clinical trials​ to life.”

“Through the KinderPharm integration, our clients will be able to benefit from a single source model,” ​Powell told us.

The single source model will offer pharmacometric modeling and clinical trial simulation technologies, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis.

Powell added, “KinderPharm also brings a focus on the development of novel and rare pediatric drugs through pediatric formulation and juvenile toxicology expertise, as well as extensive US and European pediatric regulatory experience.”

Martin Graham, PhD, KinderPharm CEO and founder, will join the team as senior vice president of pediatric development, leading Synteract’s Center of Pediatric Development. 

Graham will be joined by KinderPharm’s Lynne Georgopoulos, vice president pediatric development, Americas, and Synteract’s Dr. Martine Dehlinger-Kremer, vice president pediatric development, Europe, to build a leadership team.

Synteract earlier this year announced​ pediatrics as one of its “therapeutic centers of development.”​ Other centers include oncology, neuro-degenerative disorders, rare and orphan diseases, as well as dermatology – following the acquisition​ of Cu-Tech in July.

KinderPharm was previously involved in a strategic alliance with Worldwide Clinical Trials​ (WCT). Announced in April of this year, the alliance established a center of excellence for pediatric drug development and research. The relationship had since been dissolved.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us